As of November 6, 2026, Arbutus Biopharma Corp is a publicly traded company (Nasdaq: ABUS). The largest holder reporting an active stake on Schedule 13D is Roivant Sciences Ltd., at 19.5%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Morgan Stanley (12.2%), Two Seas Capital LP (9.4%), Whitefort Capital Master Fund, LP (8%) (Schedule 13D/A, October 5, 2026).
Is this your company?
About to sign with, pay or invest in Arbutus Biopharma Corp? See the free Snapshot first.
Free to see. No signup.
Is Arbutus Biopharma Corp a real, registered company?
- Arbutus Biopharma Corp files with the SEC under CIK 1447028 (its SEC filings).
- Its shares are listed under the ticker ABUS on Nasdaq (SEC company record).
- Incorporated in A1; business address in Warminster, Pennsylvania, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Arbutus Biopharma Corp in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names BlackRock (filed 2026-10-27).
Who are Arbutus Biopharma Corp's owners and officers?
Arbutus Biopharma Corp: business address in Warminster, Pennsylvania; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-10-27).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-10-27 | Blackrock, Inc. | 7.2% |
| Schedule 13G/A, 2026-10-07 | Morgan Stanley | 12.2% |
| Schedule 13D/A, 2026-10-05 | Roivant Sciences LTD. | 19.5% |
| Schedule 13G, 2026-09-04 | Whitefort Capital Master Fund, LP | 8% |
| Schedule 13G/A, 2026-08-12 | Morgan Stanley | 8.8% |
| Schedule 13G/A, 2026-05-15 | Two Seas Capital LP | 9.4% |
| Schedule 13D/A, 2026-04-28 | Whitefort Capital Management, LP | 8% |
| Schedule 13D/A, 2026-04-13 | Whitefort Capital Management, LP | 8.1% |
| Schedule 13G/A, 2026-02-17 | Two Seas Capital LP | 6.5% |
| Schedule 13G/A, 2026-02-11 | Morgan Stanley | 13.5% |
| Schedule 13G, 2025-08-13 | Two Seas Capital LP | 5.4% |
Questions about who owns Arbutus Biopharma Corp
Who owns Arbutus Biopharma Corp?
On this page, 6 holders' latest ownership filings report 5% or more of Arbutus Biopharma Corp: Roivant Sciences LTD. (19.5%, Schedule 13D/A, filed 2026-10-05), Morgan Stanley (12.2%, Schedule 13G/A, filed 2026-10-07), Two Seas Capital LP (9.4%, Schedule 13G/A, filed 2026-05-15), Whitefort Capital Master Fund, LP (8%, Schedule 13G, filed 2026-09-04) and Whitefort Capital Management, LP (8%, Schedule 13D/A, filed 2026-04-28); 1 more is listed above.
Who are the largest shareholders of Arbutus Biopharma Corp?
By the share each holder's latest filing reports, the largest holders of Arbutus Biopharma Corp on this page are Roivant Sciences LTD. (19.5%), Morgan Stanley (12.2%) and Two Seas Capital LP (9.4%).
When did Roivant Sciences LTD. buy into Arbutus Biopharma Corp?
The filings give report dates, not purchase dates. The earliest filing from Roivant Sciences LTD. on this page is the Schedule 13D/A, filed 2026-10-05, reporting 19.5%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 11 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Arbutus Biopharma Corp?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Arbutus Biopharma Corp: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Arbutus Biopharma Corp covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Arbutus Biopharma Corp shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director and 10% owner: 38,847,462 shares (19.6% of shares outstanding), held indirectly through By Roivant Sciences Ltd. (Form 3, 2025-03-06).
- Roivant Sciences Ltd., a director and 10% owner: 29,880,079 shares (15.1% of shares outstanding) (Form 4, 2026-10-05).
- , the chief executive and president: 1,658,003 shares (0.84% of shares outstanding) (Form 4, 2025-02-19).
- , the chief financial officer: 249,824 shares (0.13% of shares outstanding) (Form 4, 2025-02-19).
- , the chief medical officer: 155,494 shares (0.08% of shares outstanding) (Form 4, 2025-02-19).
Shares outstanding: 197,847,835 as of 2026-08-10, from the company's latest SEC cover page.
How much has Arbutus Biopharma Corp raised?
No fundraising or offering filing from Arbutus Biopharma Corp is on file with us.
Keep reading
More on Arbutus Biopharma Corp and the records around it.
Arbutus Biopharma Corp elsewhere on the record
- 5%+ stake filings Oct 2026
Companies that share a holder
- Roivant Sciences Ltd. also filed stake reports on 1 other company: Immunovant, Inc. (Dec 2025)
- Whitefort Capital Master Fund, LP also filed stake reports on 3 other companies: OmniAb, Inc. (Aug 2026), Bally's Corp (Mar 2026), INNOVATE Corp. (Nov 2025)
- Two Seas Capital LP also filed stake reports on 14 other companies: NEKTAR THERAPEUTICS (Sep 2026), Calumet, Inc. (Aug 2026), Quantum Corporation (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/arbutus-biopharma